Selected research
Industry Research
Psoriatic Arthritis Drugs Industry Research Report 2026
Market perspective
The global Psoriatic Arthritis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Psoriatic Arthritis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Psoriatic Arthritis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Psoriatic Arthritis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Psoriatic Arthritis Drugs include Janssen, Eli-Lilly, Pfizer, Amgen, Abbvie and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Psoriatic Arthritis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Psoriatic Arthritis Drugs Market by Company
Janssen
Eli-Lilly
Pfizer
Amgen
Abbvie
Celgene
Psoriatic Arthritis Drugs Segment by Type
PDE4 Inhibitors
TNF Inhibitors
Interleukin Blockers
Other
Psoriatic Arthritis Drugs Segment by Application
Moderate Psoriatic Arthritis
Severe Psoriatic Arthritis
Mild Psoriatic Arthritis
Psoriatic Arthritis Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriatic Arthritis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psoriatic Arthritis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriatic Arthritis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Psoriatic Arthritis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Psoriatic Arthritis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Psoriatic Arthritis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PDE4 Inhibitors
- TNF Inhibitors
- Interleukin Blockers
- Other
Applications
- Moderate Psoriatic Arthritis
- Severe Psoriatic Arthritis
- Mild Psoriatic Arthritis
Companies covered
- Janssen
- Eli-Lilly
- Pfizer
- Amgen
- Abbvie
- Celgene
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Psoriatic Arthritis Drugs Market Size (2021-2032)
- 2.2.2 Global Psoriatic Arthritis Drugs Sales (2021-2032)
- 2.2.3 Global Psoriatic Arthritis Drugs Market Average Price (2021-2032)
- 2.3 Psoriatic Arthritis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 PDE4 Inhibitors
- 2.3.3 TNF Inhibitors
- 2.3.4 Interleukin Blockers
- 2.3.5 Other
- 2.4 Psoriatic Arthritis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Moderate Psoriatic Arthritis
- 2.4.3 Severe Psoriatic Arthritis
- 2.4.4 Mild Psoriatic Arthritis
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Psoriatic Arthritis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Psoriatic Arthritis Drugs Sales (K Tons) of Manufacturers (2021-2026)
- 3.3 Global Psoriatic Arthritis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Psoriatic Arthritis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Psoriatic Arthritis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Psoriatic Arthritis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Psoriatic Arthritis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Psoriatic Arthritis Drugs, Established Date
- 3.9 Global Psoriatic Arthritis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Janssen
- 4.1.1 Janssen Company Information
- 4.1.2 Janssen Business Overview
- 4.1.3 Janssen Psoriatic Arthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Janssen Psoriatic Arthritis Drugs Product Portfolio
- 4.1.5 Janssen Recent Developments
- 4.2 Eli-Lilly
- 4.2.1 Eli-Lilly Company Information
- 4.2.2 Eli-Lilly Business Overview
- 4.2.3 Eli-Lilly Psoriatic Arthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eli-Lilly Psoriatic Arthritis Drugs Product Portfolio
- 4.2.5 Eli-Lilly Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Psoriatic Arthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Psoriatic Arthritis Drugs Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Amgen
- 4.4.1 Amgen Company Information
- 4.4.2 Amgen Business Overview
- 4.4.3 Amgen Psoriatic Arthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amgen Psoriatic Arthritis Drugs Product Portfolio
- 4.4.5 Amgen Recent Developments
- 4.5 Abbvie
- 4.5.1 Abbvie Company Information
- 4.5.2 Abbvie Business Overview
- 4.5.3 Abbvie Psoriatic Arthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Abbvie Psoriatic Arthritis Drugs Product Portfolio
- 4.5.5 Abbvie Recent Developments
- 4.6 Celgene
- 4.6.1 Celgene Company Information
- 4.6.2 Celgene Business Overview
- 4.6.3 Celgene Psoriatic Arthritis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Celgene Psoriatic Arthritis Drugs Product Portfolio
- 4.6.5 Celgene Recent Developments
5 Global Psoriatic Arthritis Drugs Market Scenario by Region
- 5.1 Global Psoriatic Arthritis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Psoriatic Arthritis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Psoriatic Arthritis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Psoriatic Arthritis Drugs Sales by Region: 2027-2032
- 5.3 Global Psoriatic Arthritis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Psoriatic Arthritis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Psoriatic Arthritis Drugs Revenue by Region: 2027-2032
- 5.4 North America Psoriatic Arthritis Drugs Market Facts & Figures by Country
- 5.4.1 North America Psoriatic Arthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Psoriatic Arthritis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Psoriatic Arthritis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Psoriatic Arthritis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Psoriatic Arthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Psoriatic Arthritis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Psoriatic Arthritis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Psoriatic Arthritis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Psoriatic Arthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Psoriatic Arthritis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Psoriatic Arthritis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Psoriatic Arthritis Drugs Market Facts & Figures by Country
- 5.7.1 South America Psoriatic Arthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Psoriatic Arthritis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Psoriatic Arthritis Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Psoriatic Arthritis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Psoriatic Arthritis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Psoriatic Arthritis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Psoriatic Arthritis Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Psoriatic Arthritis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Psoriatic Arthritis Drugs Sales by Type (2021-2032) & (K Tons)
- 6.1.2 Global Psoriatic Arthritis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Psoriatic Arthritis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Psoriatic Arthritis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Psoriatic Arthritis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Psoriatic Arthritis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Psoriatic Arthritis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Psoriatic Arthritis Drugs Sales by Application (2021-2032) & (K Tons)
- 7.1.2 Global Psoriatic Arthritis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Psoriatic Arthritis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Psoriatic Arthritis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Psoriatic Arthritis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Psoriatic Arthritis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Psoriatic Arthritis Drugs Value Chain Analysis
- 8.1.1 Psoriatic Arthritis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Psoriatic Arthritis Drugs Production Mode & Process
- 8.2 Psoriatic Arthritis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Psoriatic Arthritis Drugs Distributors
- 8.2.3 Psoriatic Arthritis Drugs Customers
9 Global Psoriatic Arthritis Drugs Analyzing Market Dynamics
- 9.1 Psoriatic Arthritis Drugs Industry Trends
- 9.2 Psoriatic Arthritis Drugs Industry Drivers
- 9.3 Psoriatic Arthritis Drugs Industry Opportunities and Challenges
- 9.4 Psoriatic Arthritis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst